D.A. Davidson & CO. Has $2.11 Million Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX)

D.A. Davidson & CO. trimmed its position in Anixa Biosciences, Inc. (NASDAQ:ANIX) by 8.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 671,072 shares of the company’s stock after selling 65,343 shares during the quarter. D.A. Davidson & CO.’s holdings in Anixa Biosciences were worth $2,114,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nations Financial Group Inc. IA ADV raised its stake in shares of Anixa Biosciences by 50.0% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares in the last quarter. Virtu Financial LLC increased its stake in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the period. International Assets Investment Management LLC raised its position in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Concorde Asset Management LLC bought a new position in Anixa Biosciences during the second quarter worth about $31,000. Finally, Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares in the last quarter. 29.13% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ANIX shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th. Finally, EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Trading Down 0.3 %

NASDAQ:ANIX opened at $3.30 on Friday. The stock has a market capitalization of $106.19 million, a P/E ratio of -8.54 and a beta of 0.84. Anixa Biosciences, Inc. has a 1 year low of $2.14 and a 1 year high of $5.13. The firm has a 50 day moving average of $3.24 and a 200-day moving average of $3.00.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. As a group, analysts forecast that Anixa Biosciences, Inc. will post -0.42 EPS for the current fiscal year.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.